ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
ResMed (RMD) Tops Q3 EPS by 3c, Revenues Miss
April 29, 2021 4:26 PM EDTResMed (NYSE: RMD) reported Q3 EPS of $1.30, $0.03 better than the analyst estimate of $1.27. Revenue for the quarter came in at $768.8 million versus the consensus estimate of $793.17 million.
Third Quarter 2021 HighlightsAll comparisons are to the prior year period
Revenue was comparable at $768.8 million; down 3% on a constant currency basisGAAP gross margin of 58.2%; non-GAAP gross margin contracted 40 bps to 59.6%Net operating profit increased 3%; non-GAAP operating profit up 2%GAAP diluted earnings... More